'Adc development' presentation slideshows

Antibody drug Conjugates

Based on advanced technology and years of experience, Creative Biolabs offers a variety of customized antibody drug conjugates, linker-Toxin products, ADCs cytotoxin, ADCs linkers, Anti-drug Abs and Anti-Ab ADCs for your ADC projects and promote your progress in ADC development

1.45k views • 20 slides

Antibody drug Conjugates

https://www.creative-biolabs.com/adc/target-list-customized-adcs-1.htm Based on advanced technology and years of experience, Creative Biolabs offers a variety of ADC custom products, linker-Toxin products, ADCs cytotoxin, ADCs linkers, Anti-drug Abs and Anti-Ab ADCs for your ADC projects and promote your progress in ADC development

235 views • 20 slides

ADC Payload

Antibody-drug conjugates (ADCs) are next-generation targeted anti-tumor agents that are constructed by the covalent coupling of a monoclonal antibody with a cytotoxic payload drug via a small molecular linker. As a key factor in an ADC, the payload drug dictates its efficacy.

368 views • 12 slides

Seattle Genetics Launched the Phase II Clinical Trial of Antibody-drug Conjugate (ADC) Called Enfortumab Vedotin

Enfortumab vedotin is an experimental ADC drug linked by a monoclonal antibody targeting the nectin-4 protein and a microtubule disruptor vedotin (MMAE) via Seattle Genetics' proprietary conjugated technology.

102 views • 2 slides

FDA Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

"Sacituzumab govitecan, the most advanced candidate in Immunomedics, is a novel first-in-class ADC drug consisting of anti-TROP-2 monoclonal antibody and cytotoxic SN-38. In contrast, Immunomedics uses the moderately toxic drug SN-38 instead of the super cytotoxic drug calicheamicin. "

134 views • 2 slides

Seattle Genetics Launched the Phase II Clinical Trial of Antibody-drug Conjugate (ADC) Called Enfortumab Vedotin

24 views • 2 slides

FDA Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

Sacituzumab govitecan, the most advanced candidate in Immunomedics, is a novel first-in-class ADC drug consisting of anti-TROP-2 monoclonal antibody and cytotoxic SN-38. In contrast, Immunomedics uses the moderately toxic drug SN-38 instead of the super cytotoxic drug calicheamicin. Learn more from https://www.creative-biolabs.com/blog/adc/fda-grants-priority-review-for-sacituzumab-govitecan-triple-negative-breast-cancer/

26 views • 2 slides